Content area
Full text
[Image omitted] - (http://www.fiercebiotech.com/story/molecular-partners-plots-134m-ipo-some-rd-me-time/2014-09-23) On the heels of some A-list biopharma partnerships, Switzerland's Molecular Partners (http://www.fiercebiotech.com/tags/molecular-partners) is looking to double down on its in-house projects, swinging for a $134 million IPO to help pay its way.
The company, headquartered in Zurich, expects to list its shares on the local SIX exchange by year's end, planning to spend its new funds on R&D, in-licensing and some potential acquisitions.
To date, Molecular Partners has made its name as a go-to collaborator for drugmakers with an eye on protein therapeutics, striking deals with Roche ($RHHBY), Allergan ($AGN) and Johnson & Johnson ($JNJ). Those agreements, which have brought in about $172 million and...